PainReform Ltd. (PRFX)
NASDAQ: PRFX · Real-Time Price · USD
1.040
-0.360 (-25.71%)
At close: Nov 20, 2024, 4:00 PM
0.960
-0.080 (-7.69%)
After-hours: Nov 20, 2024, 7:49 PM EST
PainReform Employees
PainReform had 7 employees as of December 31, 2023. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$2,524,714
Market Cap
2.32M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7 | 1 | 16.67% |
| Dec 31, 2022 | 6 | 2 | 50.00% |
| Dec 31, 2021 | 4 | 2 | 100.00% |
| Dec 31, 2020 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CareMax | 1,450 |
| Aditxt | 47 |
| Oncternal Therapeutics | 30 |
| Bio-Path Holdings | 10 |
| Enveric Biosciences | 7 |
| Oragenics | 5 |
| Quoin Pharmaceuticals | 4 |
PRFX News
- 20 hours ago - PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial - GlobeNewsWire
- 13 days ago - PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement - GlobeNewsWire
- 2 months ago - PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110 - GlobeNewsWire
- 2 months ago - PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds - GlobeNewsWire
- 3 months ago - PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study - GlobeNewsWire
- 3 months ago - PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses - GlobeNewsWire
- 3 months ago - PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature - GlobeNewsWire
- 6 months ago - PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification - GlobeNewsWire